Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy

被引：0
|
作者：
Penel, Nicolas
Demetri, George D.
Blay, Jean-Yves
Cousin, Sophie
Maki, Robert G.
Chawla, Sant P.
Judson, Ian Robert
von Mehren, Margaret
Schoffski, Patrick
Verweij, Jaap
Casali, Paolo Giovanni
Rodenhuis, Sjoerd
Gomez, Javier
Nieto, Antonio
Zintl, Patrik
Valero, Maria Jose Pontes
Cassar, Alexia
Le Cesne, Axel
机构：
[1] Ctr Oscar Lambret, F-59020 Lille, France
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Lyon 1, Ctr Leon Berard, F-69365 Lyon, France
[4] Mt Sinai Sch Med, New York, NY USA
[5] Sarcoma Oncol Ctr, Santa Monica, CA USA
[6] Royal Marsden NHS Fdn Trust, London, England
[7] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[8] Catholic Univ Louvain, Leuven Canc Inst, Dept Gen Med Oncol, B-3000 Louvain, Belgium
[9] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[10] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[11] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[12] PharmaMar, Madrid, Spain
[13] Quintiles, Levallois Perret, France
[14] Inst Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10013
引用
收藏
页数：1
相关论文
共 32 条
  • [1] Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy
    Penel, N.
    Demetri, G. D.
    Blay, J. Y.
    Cousin, S.
    Maki, R. G.
    Chawla, S. P.
    Judson, I.
    von Mehren, M.
    Schoffski, P.
    Verweij, J.
    Casali, P.
    Rodenhuis, S.
    Schuette, H. J.
    Cassar, A.
    Gomez, J.
    Nieto, A.
    Zintl, P.
    Pontes, M. J.
    Le Cesne, A.
    ANNALS OF ONCOLOGY, 2013, 24 (02) : 537 - 542
  • [2] Growth modulation index and RECIST-based STBSG-EORTC criteria for the assessment of drug activity in advanced soft tissue sarcoma (ASTS) patients (pts)
    Cousin, Sophie
    Blay, Jean-Yves
    Bertucci, Francois
    Isambert, Nicolas
    Italiano, Antoine
    Bompas, Emmanuelle
    Ray-Coquard, Isabelle
    Perrot, Delphine
    Binh Bui Nguyen
    Chaix, Marie
    Chaigneau, Loic
    Corradini, Nadege
    Penel, Nicolas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
    A Laroche-Clary
    V Chaire
    V Le Morvan
    A Neuville
    F Bertucci
    S Salas
    R Sanfilippo
    P Pourquier
    A Italiano
    British Journal of Cancer, 2015, 112 : 688 - 692
  • [4] Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin
    Simetic, Luka
    Blazicevic, Kresimir
    Ladenhauser, Tatjana
    Golcic, Marin
    Majnaric, Tea
    Herceg, Davorin
    ANTI-CANCER DRUGS, 2021, 32 (10) : 1058 - 1066
  • [5] BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
    Laroche-Clary, A.
    Chaire, V.
    Le Morvan, V.
    Neuville, A.
    Bertucci, F.
    Salas, S.
    Sanfilippo, R.
    Pourquier, P.
    Italiano, A.
    BRITISH JOURNAL OF CANCER, 2015, 112 (04) : 688 - 692
  • [6] Trabectedin in patients with advanced soft tissue sarcoma (STS): importance of maintenance therapy in responding patients after 6 cycles of trabectedin
    Le Cesne, A.
    Ray-Coquard, I.
    Duffaud, F.
    Chevreau, C.
    Penel, N.
    Bui, B.
    Piperno-Neumann, S.
    Even, C.
    Cousin, P.
    Blay, J. Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S887 - S887
  • [7] Correlation between a new growth modulation index (GMI)-based Geistra score and efficacy outcomes in patients (PTS) with advanced soft tissue sarcomas (ASTS) treated with trabectedin (T): A Spanish group for research on sarcomas (GEIS-38 study).
    Martinez-Trufero, Javier
    Hindi, Nadia
    Cruz, Josefina
    Alvarez, Rosa Maria Alvarez
    Beveridge, Roberto Pedro Diaz
    Morales, Claudia Maria Valverde
    Gutierrez, Antonio
    Bernad, Isabel Pajares
    Lopez-Pousa, Antonio
    Salgado, Maria Angeles Vaz
    Lavernia, Javier
    Cano, Juana Maria
    Sevilla, Isabel
    Rubio-Casadevall, Jordi
    De Juan, Ana
    Carrasco, Juan Antonio
    Leon, Nieves Hernandez
    Pujol, Carolina Agra
    Lamana, Lucia Ferrando
    Broto, Javier Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Clinical benefit and fragility evaluation of systemic therapy trials for advanced soft tissue sarcoma
    Braik, Dina
    Lemieux, Christopher
    Wilson, Brooke E.
    Salawu, Abdulazeez
    Razak, Albiruni R. Abdul
    CANCER, 2025, 131 (01)
  • [9] Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin
    Vincenzi, Bruno
    Badalamenti, Giuseppe
    Armento, Grazia
    Silletta, Marianna
    Ceruso, Mariella Spalato
    Catania, Giovanna
    Napolitano, Andrea
    Maltese, Giuseppa
    Valeri, Sergio
    Incorvaia, Lorena
    Santini, Daniele
    Tonini, Giuseppe
    ONCOLOGY, 2018, 95 (01) : 1 - 7
  • [10] Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS)
    Kotecki, N.
    Le Cesne, A.
    Tresch-Bruneel, E.
    Mir, O.
    Chevreau, C.
    Bertucci, F.
    Delcambre, C.
    Saada-Bouzid, E.
    Piperno-Neumann, S.
    Bay, J-O.
    Ray-Coquard, L.
    Ryckewaert, T.
    Isambert, N.
    Italiano, A.
    Clisant, S.
    Blay, J-Y.
    Penel, N.
    ANNALS OF ONCOLOGY, 2016, 27
1234